Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Last updated: October 23, 2025
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Control Group

Standard of Care

Clinical Study ID

NCT05205343
2021-0914
NCI-2022-00267
  • Ages > 18
  • All Genders

Study Summary

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Eligibility Criteria

Inclusion

Inclusion:

  1. Able to speak and read English, Spanish, Japanese or Korean

  2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention

  3. Age ≥ 18

Exclusion:

  1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract

  2. Participants with known narcotic dependence, with average daily dose > 5 mg oral morphine equivalent

  3. Participants deemed unable to comply with study and/or follow-up procedures, at investigators' discretion

  4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: Control Group
Phase:
Study Start date:
May 11, 2022
Estimated Completion Date:
May 31, 2026

Study Description

Primary Objective:

Delineate the short-term appetite of patients who undergo minimally-invasive proximal gastrectomy (MIPG) and compare them with those of patients with gastric and gastroesophageal adenocarcinoma who undergo total gastrectomy (MITG). We hypothesize that MIPG is associated with better postoperative appetite levels compared to MITG, which would result in improved nutritional status and maintained body weight after surgery.

Secondary Objective:

  • Assess patient-reported outcomes (PROs) and nutrition measures. We will use the MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI) questionnaire with additional three experimental question items ("PRO questionnaire") to collect preoperative and postoperative patient-reported outcomes (PROs) of QoL and check fasting ghrelin levels to correlate them with reported appetite levels. We will also retrospectively investigate factors associated with improved QoL after surgery, safety of MIPG and MITG, and oncological outcomes after MIPG and MITG.

Connect with a study center

  • Keio University School of Medicine

    Tokyo, 1600016
    Japan

    Site Not Available

  • Keio University School of Medicine

    Tokyo 1850147, 1600016
    Japan

    Active - Recruiting

  • Yonsei University College of Medicine

    Soeul, 03722
    Korea, Democratic People's Republic of

    Active - Recruiting

  • Yonsei University College of Medicine

    Soeul, 03722
    Korea, Republic of

    Site Not Available

  • Yonsei University College of Medicine

    Soeul 6808867, 03722
    South Korea

    Active - Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • Mayo Clinic in Rochester

    Rochester 5043473, Minnesota 5037779 55905
    United States

    Active - Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Site Not Available

  • Weill Cornell Medical College of Cornell University

    New York, New York 10065
    United States

    Site Not Available

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

  • M D Anderson Cancer Center

    Houston 4699066, Texas 4736286 77030
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.